Equity crowdfunding platform OurCrowd has launched a $10m fund targeting seed-stage companies.

Medtech firm NeuWave secures $25m in series C backing to commercialise Wisconsin technology.

Texas University spin-out Pulmotect breathes in $3m grant from NIH.

GlaxoSmithKline and Google both exited the biotechnology developer through the $175m acquisition, which could eventually rise to $725m.

Merck will pay $106m for a 15% stake in NGM as part of a five-year, $450m diabetes and obesity treatment development deal with the biotechnology company.

The two companies have signed a collaboration and license agreement worth up to $615m, with Seattle Genetics committing $25m upfront and another $5m in equity.

Spero will use the funding, raised from backers including Lundbeck, Merck and GlaxoSmithKline, to advance its anti-infectives pipeline.